The inventory quoted a 52-week excessive value of Rs 742.25 and a low of Rs 494.75. The return on fairness for the inventory stood at 10.77 per cent. About 21,217 shares have modified palms on the counter to this point.
The inventory’s beta worth, which measures its volatility in relation to the broader market, stood at 1.06.
The scrip has been an underperformer, down 27.84 per cent up to now one 12 months compared with a 3.79 per cent fall in Sensex.
On the technical charts, the 200-day transferring common (DMA) of the inventory stood at Rs 494.75 on October 18, whereas the 50-DMA was at Rs 541.43. If a inventory trades properly above 50-DMA and 200-DMA, it normally means the speedy development is upward. Then again, if the inventory trades properly beneath 50-DMA and 200-DMA each, it’s thought-about a bearish development and if trades between these averages, then it suggests the inventory can go both manner.
Promoters held 48.76 per cent stake in Aurobindo Pharma Ltd. as of 30-Jun-2022. Mutual funds and international institutional buyers held 9.82 per cent and 20.71 per cent stake.